Compare · DCOY vs NVO
DCOY vs NVO
Side-by-side comparison of Decoy Therapeutics Inc. (DCOY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCOY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 110355.2x DCOY ($2.0M).
- Over the past year, DCOY is down 95.3% and NVO is down 12.1% - NVO leads by 83.2 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for DCOY).
- NVO has more recent analyst coverage (25 ratings vs 1 for DCOY).
- Company
- Decoy Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $3.25-1.22%
- $48.65+3.65%
- Market cap
- $2.0M
- $215.46B
- 1M return
- -13.56%
- -2.08%
- 1Y return
- -95.29%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 5
- 9
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DCOY
- SEC Form SCHEDULE 13G filed by Decoy Therapeutics Inc.
- SEC Form 10-Q filed by Decoy Therapeutics Inc.
- SEC Form DEF 14A filed by Decoy Therapeutics Inc.
- SEC Form DEFA14A filed by Decoy Therapeutics Inc.
- Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
- SEC Form 3 filed by new insider Gauthier Patricia G.
- Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
- SEC Form PRE 14A filed by Decoy Therapeutics Inc.
- SEC Form EFFECT filed by Decoy Therapeutics Inc.
- SEC Form 424B3 filed by Decoy Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S